| Literature DB >> 25710028 |
Bogusława Orzechowska-Wylęgała1, Adam Wylęgała2, Michał Buliński1, Iwona Niedzielska1.
Abstract
OBJECTIVES: There is no single pattern for preventive action as to the duration and type of antibiotic therapy in maxillofacial surgery. In these circumstances, it appears reasonable to set relevant standards for prophylactic procedures after such surgeries.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25710028 PMCID: PMC4331397 DOI: 10.1155/2015/819086
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The number of the patients subject to the examination with gender breakdown.
| Gender | Years | Total | ||||
|---|---|---|---|---|---|---|
| 2008 | 2009 | 2010 | 2011 | 2012 | ||
| M | 31 | 63 | 61 | 59 | 70 | 284 |
| F | 23 | 48 | 33 | 47 | 49 | 200 |
|
| ||||||
| Total | 484 | |||||
Types of swabs taken over the years.
| Swab origin | Year | ||||
|---|---|---|---|---|---|
| 2008 | 2009 | 2010 | 2011 | 2012 | |
| Abscess | 21 | 98 | 73 | 65 | 78 |
| Sinus | 25 | 44 | 20 | 24 | 27 |
| Dermal fistula | 5 | 13 | 17 | 38 | 44 |
| Bone | 1 | — | 7 | 8 | 11 |
| Wound | 9 | — | 7 | 12 | 25 |
| Oral cavity | 2 | 5 | 4 | 3 | 6 |
| Pharynx | 11 | — | 2 | 4 | 2 |
| Nose | 1 | — | — | — | — |
| Urine | 2 | — | — | — | — |
| Blood | — | 2 | 4 | — | 6 |
|
| |||||
| Total | 77 | 162 | 134 | 154 | 199 |
Microorganisms isolated from 484 patients treated at the Cranio-Maxillo-Facial Surgery Chair and Clinic and the Clinical Outpatient Unit for Maxillofacial Surgery.
| Microorganism | 2008 | 2008% | 2009 | 2009% | 2010 | 2010% | 2011 | 2011% | 2012 | 2012% | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Coagulase (−) | 7 | 9.09 | 33 | 20.37 | 47 | 35.07 | 41 | 26.62 | 38 | 19.10 | 166 |
| MRSA | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 1.01 | 2 |
| MSSA | 14 | 18.18 | 10 | 6.17 | 13 | 9.70 | 9 | 5.84 | 8 | 4.02 | 54 |
| Other G (+) cocci | 4 | 5.19 | 13 | 1.23 | 5 | 3.73 | 5 | 3.25 | 2 | 1.01 | 29 |
|
| 7 | 9.09 | 11 | 6.79 | 11 | 8.21 | 24 | 15.58 | 29 | 14.57 | 82 |
| Other | 10 | 12.99 | 21 | 12.96 | 16 | 11.94 | 16 | 10.39 | 26 | 13.07 | 89 |
|
| 10 | 12.99 | 13 | 8.02 | 10 | 7.46 | 2 | 1.30 | 9 | 4.52 | 44 |
| Viridans streptococci | 3 | 3.90 | 8 | 4.94 | 0.00 | 9 | 5.84 | 26 | 13.07 | 46 | |
|
| 3 | 3.90 | 4 | 2.47 | 2 | 1.49 | 8 | 5.19 | 6 | 3.02 | 23 |
| Total cocci | 58 | 75.32 | 113 | 69.75 | 104 | 77.61 | 114 | 74.03 | 146 | 73.37 | 535 |
| Other G (+) | 0 | 0.00 | 2 | 1.23 | 1 | 0.75 | 1 | 0.65 | 2 | 1.01 | 6 |
| Total G (+) |
|
|
|
|
|
|
|
|
|
|
|
|
| 5 | 6.49 | 10 | 6.17 | 5 | 3.73 | 5 | 3.25 | 10 | 5.03 | 35 |
|
| 3 | 3.90 | 11 | 6.79 | 4 | 2.99 | 5 | 3.25 | 10 | 5.03 | 33 |
|
| 3 | 3.90 | 1 | 0.62 | 1 | 0.75 | 0 | 0.00 | 4 | 2.01 | 9 |
| Enterobacteriaceae | 3 | 3.90 | 3 | 1.85 | 1 | 0.75 | 0 | 0.00 | 6 | 3.02 | 13 |
|
| 1 | 1.30 | 7 | 4.32 | 10 | 7.46 | 8 | 5.19 | 6 | 3.02 | 32 |
|
| 0 | 0.00 | 1 | 0.62 | 1 | 0.75 | 1 | 0.65 | 0 | 0.00 | 3 |
|
| 1 | 1.30 | 3 | 1.85 | 2 | 1.49 | 1 | 0.65 | 4 | 2.01 | 11 |
|
| 1 | 1.30 | 2 | 1.23 | 1 | 0.75 | 3 | 1.95 | 1 | 0.50 | 8 |
|
| 0 | 0.00 | 5 | 3.09 | 4 | 2.99 | 5 | 3.25 | 4 | 2.01 | 18 |
| Other G (−) | 1 | 1.30 | 3 | 1.85 | 0 | 0.00 | 8 | 5.19 | 3 | 1.51 | 18 |
| Total G (−) |
|
|
|
|
|
|
|
|
|
|
|
|
| 1 | 1.30 | 1 | 0.62 | 0 | 0 | 3 | 1.95 | 3 | 1.51 |
|
|
| |||||||||||
| Total microorganisms |
|
|
|
|
|
|
|
|
|
|
|
G (+): Gram+ bacteria; G (−): Gram− bacteria.
List of alert pathogens.
| Microorganism | Year | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2008 | 2008% | 2009 | 2009% | 2010 | 2010% | 2011 | 2011% | 2012 | 2012% | ||
| MRSA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1.01 | 2 |
|
| 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0.50 | 3 |
|
| 0 | 0 | 0 | 0 | 1 | 0.75 | 0 | 0 | 0 | 0 | 1 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1.01 | 2 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1.51 | 3 |
|
| 1 | 1.32 | 2 | 1.23 | 2 | 1.49 | 0 | 0 | 2 | 1.01 | 7 |
|
| 0 | 0 | 1 | 0.62 | 1 | 0.75 | 0 | 0 | 2 | 1.01 | 4 |
|
| 1 | 1.32 | 0 | 0 | 0 | 0 | 1 | 0.65 | 0 | 0 | 2 |
|
| |||||||||||
| Total | 2 | 5 | 4 | 1 | 12 | 24 | |||||
Figure 1Susceptibility of Gram-positive and Gram-negative bacteria to ampicillin, compared in 2008–2010 and 2011-2012.
Figure 2Susceptibility of Gram-positive and Gram-negative bacteria to gentamicin, compared in 2008–2010 and 2011-2012.
Susceptibility of Gram-positive and Gram-negative bacteria to antibiotics in 2008–2010 and 2011-2012.
| Antibiotic | Gram-positive | Gram-negative | ||||
|---|---|---|---|---|---|---|
| 2008–2010 | 2011-2012 | 5 years | 2008–2010 | 2011-2012 | 5 years | |
| Ampicillin | 124 (89.9%) | 93 (69.9%) | 223 (82%) | 27 (36.5%) | 17 (38.6%) | 44 (37.3%) |
| Amoxicillin clavulanate | N/A | N/A | N/A | 42 (64.6%) | 28 (60.9%) | 70 (63%) |
| Ciprofloxacin | 75 (87.2%) | 20 (80%) | 95 (85.6%) | 60 (87%) | 25 (89.3%) | 85 (87.6%) |
| Sulfamethoxazole/ trimethoprim | 139 (91.4%) | 139 (82.4%) | 275 (86.7%) | 40 (75.5%) | 54 (77.14%) | 94 (74%) |
| Gentamicin | 105 (94.6%) | 86 (84.3%) | 191 (89.7%) | 51 (94.4%) | 56 (87.5%) | 107 (90.7%) |
| Vancomycin | 248 (100%) | 260 (98.8%) | 508 (99.4%) | N/A | N/A | N/A |
| Imipenem | 22 (100%) | 30 (83.3%) | 52 (89.6%) | 69 (92%) | 5 (90%) | 123 (91.1%) |
| Clindamycin | 171 (66.8%) | 148 (61.4%) | 319 (64.2%) | N/A | N/A | N/A |
| Penicillin | 135 (53.4%) | 119 (50.4%) | 254 (51.9%) | N/A | N/A | N/A |
N/A: not applicable.